Nyxoah S.A. (NASDAQ:NYXH) Sees Significant Increase in Short Interest

Nyxoah S.A. (NASDAQ:NYXHGet Rating) was the recipient of a large increase in short interest in the month of May. As of May 15th, there was short interest totalling 6,300 shares, an increase of 117.2% from the April 30th total of 2,900 shares. Approximately 0.1% of the company’s shares are sold short. Based on an average trading volume of 3,400 shares, the days-to-cover ratio is currently 1.9 days.

Shares of NYXH opened at $13.00 on Friday. The company has a quick ratio of 10.38, a current ratio of 10.41 and a debt-to-equity ratio of 0.07. The firm’s fifty day simple moving average is $16.79 and its two-hundred day simple moving average is $19.27. Nyxoah has a 12 month low of $12.81 and a 12 month high of $37.00.

Large investors have recently made changes to their positions in the company. Credit Suisse AG bought a new stake in shares of Nyxoah in the 3rd quarter valued at $221,000. Jane Street Group LLC acquired a new stake in Nyxoah in the third quarter worth $228,000. Evolutionary Tree Capital Management LLC increased its stake in Nyxoah by 62.2% in the fourth quarter. Evolutionary Tree Capital Management LLC now owns 62,445 shares of the company’s stock valued at $1,436,000 after purchasing an additional 23,955 shares in the last quarter. Rossmore Private Capital raised its holdings in shares of Nyxoah by 29.7% during the fourth quarter. Rossmore Private Capital now owns 117,940 shares of the company’s stock valued at $2,494,000 after purchasing an additional 27,000 shares during the period. Finally, Allspring Global Investments Holdings LLC bought a new position in shares of Nyxoah during the 4th quarter worth about $2,895,000. 10.76% of the stock is currently owned by institutional investors.

A number of equities analysts have recently commented on the stock. Wolfe Research started coverage on shares of Nyxoah in a report on Tuesday, April 5th. They set a “market perform” rating and a $21.00 price target on the stock. Oppenheimer assumed coverage on Nyxoah in a report on Wednesday, April 20th. They set an “outperform” rating and a $30.00 target price on the stock. Piper Sandler reduced their price target on Nyxoah from $40.00 to $30.00 in a research report on Friday, March 25th. Finally, Zacks Investment Research upgraded Nyxoah from a “hold” rating to a “buy” rating and set a $16.00 price objective for the company in a research report on Thursday. One analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $30.50.

Nyxoah Company Profile (Get Rating)

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Featured Articles

Receive News & Ratings for Nyxoah Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nyxoah and related companies with MarketBeat.com's FREE daily email newsletter.